SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

SION-451

SION·Sionna Therapeutics, Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 1 completed; Phase 2a planned
Time to market
At least 4-6 years away, if successful. The AscenSION CF Phase 2a trial has not yet started (expected Q1 2027). Even in a best case, Phase 2a readout would be 12-18 months away, followed by larger Phase 3 trials and FDA review.
Why 4/10
The next hard catalyst is the start of the AscenSION CF Phase 2a trial for SION-451 + SION-2222, expected in Q1 2027 (about 4 months away). However, a trial initiation is not a binary readout; the actual Phase 2a topline data is likely 12-18 months away. SION-451 is now the company's lead asset after SION-719 failed, but it remains early-stage with no proof-of-concept data in patients yet.
Actionable Insight MIXED

Watch for the initiation of the AscenSION CF Phase 2a trial for SION-451 + SION-2222 in Q1 2027. This trial start will signal the company's ability to execute after the workforce reduction, but the real binary event will be the Phase 2a topline efficacy readout, which is likely 12-18 months away. The stock's extreme post-failure valuation ($3.57, down 92% from the high) and $249M cash position create an asymmetric risk/reward, but SION-451 has no clinical proof-of-concept yet in patients.

Price Chart

Loading chart...

Executive Summary

SION-451 is an NBD1 stabilizer for cystic fibrosis being developed by Sionna Therapeutics (NASDAQ: SION). After the company's lead program SION-719 failed a Phase 2a trial in August 2026 (crushing the stock by ~92%), SION-451 became the company's primary focus. It is being advanced as a dual combination with SION-2222 into a Phase 2a proof-of-concept trial (AscenSION CF) expected to start in Q1 2027. The company has a strong cash position of ~$249 million and a runway into 2029, but SION-451 has not yet demonstrated efficacy in CF patients, and the stock trades near its all-time low of $3.19 after the devastating trial failure of its predecessor program.

How It Works

SION-451 is an NBD1 (nucleotide binding domain 1) stabilizer, a type of small molecule designed to fix a defective protein called CFTR that causes cystic fibrosis. In people with CF, the CFTR protein misfolds and cannot reach the cell surface to regulate salt and water. SION-451 aims to stabilize the NBD1 region of CFTR, helping the protein fold correctly and function more normally. It is being developed as a dual combination with another drug (SION-2222) that targets a different part of the CFTR protein, potentially offering a treatment that could work for a broad CF population without needing to be added to existing therapies like Vertex's Trikafta.

Trial Status

SION-451 completed Phase 1 healthy-volunteer trials with positive safety and pharmacokinetic data announced in June 2025. A Phase 1 dual-combination trial (SION-451 paired with SION-2222 or SION-109) was dosed starting August 2025, with topline data reported in August 2026. On September 14, 2026, Sionna announced plans to advance the SION-451 + SION-2222 combination into a Phase 2a proof-of-concept trial called AscenSION CF. As of the Q3 2026 earnings report (November 10, 2026), the AscenSION CF trial is expected to initiate in the first quarter of 2027.

The Two-Sided Case

▲ Bull Case1
SION-451 targets a novel mechanism (NBD1 stabilization) that could address the root cause of CFTR dysfunction, potentially offering benefit to a broader CF population than current therapies. The company has a strong cash position of approximately $249 million, funding operations into 2029, which provides a long runway to generate clinical data. Analyst price targets show a mean of $21 (488% implied upside from the $3.57 close), with 6 Buy/Strong Buy ratings versus 11 Hold and 0 Sell. Several institutional investors added or doubled positions in Q2 and Q3 2026, including Adage Capital, Goldman Sachs, and Millennium Management.
▼ Bear Case1
The company's lead program SION-719 failed its Phase 2a trial in August 2026, causing the stock to crash approximately 92% from its 52-week high of $54.97 to near $3.57. SION-451 has not yet demonstrated proof-of-concept in patients with CF; all Phase 1 data came from healthy volunteers. The company cut 46% of its workforce in September 2026, signaling significant organizational distress. Multiple analysts downgraded the stock after the August data, including Guggenheim (Buy to Neutral), Wedbush (Outperform to Neutral), and BTIG (Buy to Neutral). Major insider RA Capital Management sold over $21 million worth of shares on September 17, 2026. The AscenSION CF Phase 2a trial has not even started enrollment yet, and topline data is likely 12-18 months away.

Upcoming Catalysts

  • Initiation of AscenSION CF Phase 2a proof-of-concept trial for SION-451 + SION-2222, expected Q1 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sionna Therapeutics, Inc. PRESS-RELEASE SION ·Originating report

Sources · 11

Hover a chip for the title
1 seekingalpha.com2 msn.com3 markets.financialcontent.com4 nasdaq.com5 markets.businessinsider.com6 fiercebiotech.com7 reuters.com8 fiercebiotech.com9 biospace.com10 247wallst.com11 menafn.com